Neostigmine 15mg tablets

País: Reino Unido

Idioma: inglés

Fuente: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredientes activos:

Neostigmine bromide

Disponible desde:

Alliance Pharmaceuticals Ltd

Código ATC:

N07AA01

Designación común internacional (DCI):

Neostigmine bromide

Dosis:

15mg

formulario farmacéutico:

Oral tablet

Vía de administración:

Oral

clase:

No Controlled Drug Status

tipo de receta:

Valid as a prescribable product

Resumen del producto:

BNF: 10020100; GTIN: 5024403000240

Información para el usuario

PATIENT INFORMATION LEAFLET
NEOSTIGMINE BROMIDE 15 MG TABLETS
Neostigmine bromide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE.
•
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
•
IF YOU HAVE ANY FURTHER QUESTIONS, ASK YOUR DOCTOR OR PHARMACIST.
•
THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. DO NOT PASS IT ON TO
OTHERS.
IT MAY HARM THEM, EVEN IF THEIR SYMPTOMS ARE THE SAME AS YOURS.
•
IF ANY OF THE SIDE EFFECTS GETS SERIOUS, OR IF YOU NOTICE ANY SIDE
EFFECTS
NOT LISTED IN THIS LEAFLET, PLEASE TELL YOUR DOCTOR OR PHARMACIST.
IN THIS LEAFLET:
1.
WHAT NEOSTIGMINE BROMIDE TABLETS ARE AND WHAT THEY ARE USED FOR
2.
BEFORE YOU TAKE NEOSTIGMINE BROMIDE TABLETS
3.
HOW TO TAKE NEOSTIGMINE BROMIDE TABLETS
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE NEOSTIGMINE BROMIDE TABLETS
6.
FURTHER INFORMATION
1.
WHAT NEOSTIGMINE BROMIDE TABLETS ARE AND WHAT THEY ARE
USED FOR
Neostigmine Bromide Tablets block the action of an enzyme in the body
which
“switches off” nerve impulses to muscles. By stopping this enzyme
from working,
Neostigmine Bromide can increase muscle strength, but only in certain
conditions.
Neostigmine Bromide Tablets are used mainly for the treatment of
myasthenia
gravis, a disease in which the muscles are weak and tire easily. They
are also used
when the normal movements of the intestine are absent and for the
treatment of
urinary retention after surgery.
2.
BEFORE YOU TAKE NEOSTIGMINE BROMIDE TABLETS
YOU SHOULD NOT TAKE THESE TABLETS IF:
•
You have a blockage in your intestine which may cause vomiting,
abdominal
pain and swelling
•
You have difficulty passing water
•
You know that you are allergic to Neostigmine Bromide or any of the
other
ingredients in Section 6 of this leaflet
Make sure your doctor knows if any of these apply to you before you
take these
tablets.
BEFORE YOU TAKE NEOSTIGMINE BROMIDE TABLETS, YOUR DOCTOR WILL TAKE
SPECIAL ARE
IF ANY OF THE FOLLOWING APPLY TO YOU:
•
You suffer from asthma
•
You have a stomach ulcer
Neostigmine PIL UK 003
•
You suffer

Ficha técnica

OBJECT 1
NEOSTIGMINE BROMIDE TABLETS15MG
Summary of Product Characteristics Updated 10-Feb-2015 | Alliance
Pharmaceuticals
1. Name of the medicinal product
Neostigmine Bromide Tablets 15 mg
2. Qualitative and quantitative composition
Each tablet contains 15 mg neostigmine bromide Ph.Eur.
3. Pharmaceutical form
Tablets
4. Clinical particulars
4.1 Therapeutic indications
Myasthenia gravis; paralytic ileus; post-operative urinary retention.
4.2 Posology and method of administration
Neostigmine bromide has a slower onset of effect when given orally
than when given parenterally, but the
duration of action is longer and the intensity of action more uniform.
To facilitate change of treatment from one route of administration to
another, the following doses are
approximately equivalent in effect:
0.5 mg intravenously = 1-1.5 mg intramuscularly or subcutaneously = 15
mg orally.
Myasthenia gravis
_Adults_: Doses of 1-2 tablets by mouth are given at intervals
throughout the day when maximum strength
is needed (for example, on rising and before mealtimes). The usual
duration of action of a dose is two to
four hours.
The total daily dose is usually in the range of 5-20 tablets but doses
higher than these may be needed by
some patients.
_Newborn infants_: Neostigmine bromide ampoules are recommended.
_Older children_: Children under 6 years old should receive an initial
dose of half a tablet (7.5 mg) of
Neostigmine Bromide; children 6-12 years old should receive one tablet
(15 mg). Dosage requirements
should be adjusted according to the response but are usually in the
range of 15-90 mg orally per day.
The requirement for Neostigmine Bromide is usually markedly decreased
after thymectomy, or when
additional therapy (steroids, immunosuppressant drugs) is given.
When relatively large doses of neostigmine bromide are taken by
myasthenic patients, it may be
necessary to give atropine or other anticholinergic drugs to
counteract the muscarinic effects. It should be
noted that the slower gastro-intestinal motility caused by these drug